Clinical Trial Update: Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of gefapixant (MK-7264) for acute cough due to induced viral URTI was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Cough
• Upper Respiratory Tract Infection

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Acute Cough | Phase 2 | Status: TERMINATED | Results posted: 2019-12-10